



Press Release

Cipla Medpro (Pty) Ltd. Partners with Serum Institute India (SII) to Provide Vaccines in South Africa

Mumbai, October 8, 2015: Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that its South African subsidiary Cipla Medpro (Pty) Ltd. has entered into an exclusive agreement with the world's largest vaccine manufacturer, Serum Institute of India (SII) in South Africa. The partnership will not only enable affordable and accessible vaccines for South Africans, but will also facilitate a reliable supply stream to the South African Government.

Paul Miller, CEO of Cipla Medpro, South Africa said: "This agreement will enable Cipla Medpro to become a significant player in the market. With a presence in 140 countries and 1.3 billion doses manufactured and sold, SII is an ideal ally for Cipla Medpro and this partnership will be instrumental in addressing the national vaccine shortage."

SII manufactures a variety of vaccine classes including vaccines for Polio, Diphtheria, Tetanus, BCG (Tuberculosis), Hepatitis B, Measles, Mumps and Rubella; South Africa will be participating in the majority of these portfolios.

Michel Baijot, Head of Vaccines, Cipla Ltd., said: "This Cipla Medpro – SII agreement reflects again the complementarities of our two like-minded companies in bringing high quality, affordable vaccines to more countries."

The agreement stipulates that Cipla Medpro will become the holder of all Medical Control Council (MCC) regulatory approvals such as product registrations and marketing authorisations. Cipla Medpro has exclusivity and first right of refusal of the SII pipeline within South Africa.

Adar Poonawalla, CEO and Executive Director, SII said: "SII is looking to extend the strong partnership it has with Cipla in Europe and India by working with Cipla Medpro in South Africa."

"We are confident that this agreement will support the Department of Health in rolling out its expanded immunisation program. Cipla Medpro will continuously look to partner with organisations that are aligned with the company's ethos of advancing healthcare for all," concludes Miller.

About Cipla Ltd.:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 75 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems.

About Cipla Medpro (Pty) Ltd.:

Cipla Medpro - the third largest pharmaceutical manufacturer in South Africa - is a leading provider of affordable medicines to the public and private sectors. Cipla Medpro manufactures world class pharmaceuticals at cost-effective prices, making quality medicines affordable, and advancing healthcare for all South Africans.

About Serum Institute of India Limited (SII)

Serum Institute of India Limited is the world's second largest vaccine manufacturer in number of doses manufactured and supplied to more than 140 countries. The vaccines include Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella, Meningitis A, Influenza and Polio vaccines. One of every two children born in the world receive a vaccine manufactured by Serum Institute.

Media Contacts: Corporate Communications

Pranjali Galgali
Mobile: +91 9930540911
E-mail: pranjali.galgali@cipla.com